piR-34379 inhibits bladder cancer progression and reverses cisplatin resistance by downregulating ACAT2-mediated PKM2 lactylation
Cellular Signalling · 2027-02 · 150 · 112978
DOI: 10.1016/j.cellsig.2026.112978 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Signalling, 2027-02. Verfasst von Suyuelin Huang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China; Cancer Center, Zhejiang Univ…. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Zhejiang Province Natural Science Foundation, Key Research and Development Program of Zhejiang Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
PIWI-interacting RNAs (piRNAs) are a new type of small non-coding RNAs (ncRNAs) that interact with PIWI proteins and exert significant influence over germ cell development and malignant tumor progression. Nevertheless, the precise roles and molecular mechanisms of piRNAs in bladder cancer (BCa) remain unclear. This study first reveals that piR-34379 is profoundly underexpressed in BCa and inversely correlates with advanced pathological staging. Through both cellular and animal models, we identify that piR-34379 exerts strong anti-tumor activity in BCa, as evidenced by restraining proliferation and migration, suppressing xenograft progression, enhancing apoptosis and reversing cisplatin resistance. Mechanistically, we reveal that piR-34379 recruits the GTSF1/PIWIL2 complex to negatively regulate ACAT2 mRNA, which functions as a novel lactylation writer. Downregulation of ACAT2 reduces lactylation modification at the K428 residue of PKM2, thereby decreasing PKM2 protein stability and promoting its degradation via the HSPA8-mediated autophagy-lysosome pathway. Consequently, the oncogenic effect of the PKM2 K428 site in BCa is suppressed. Collectively, our findings establish the tumor-suppressive role of the piR-34379/GTSF1/PIWIL2-ACAT2-PKM2 axis in BCa and underscore its therapeutic promise for reversing cisplatin resistance.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China; Cancer Center, Zhejiang University, Hangzhou, Zhejiang, China. Electronic address: 22418295@zju.ed…
- Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China; Cancer Center, Zhejiang University, Hangzhou, Zhejiang, China. Electronic address: 22318584@zju.ed…
- Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China; Cancer Center, Zhejiang University, Hangzhou, Zhejiang, China. Electronic address: 22318578@zju.ed…
- Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China; Cancer Center, Zhejiang University, Hangzhou, Zhejiang, China. Electronic address: 22318195@zju.ed…
- Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China; Cancer Center, Zhejiang University, Hangzhou, Zhejiang, China.
- Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China; Cancer Center, Zhejiang University, Hangzhou, Zhejiang, China. Electronic address: 3190104261@zju.…
Förderung
- Zhejiang Province Natural Science Foundation
- Key Research and Development Program of Zhejiang Province
- National Natural Science Foundation of China
Zitieren
APA
Huang, S., Li, Y., Shi, Y., Zhang, F., Lu, D., Yu, K., Zhang, J., Yuan, J., Wang, X., Ma, X., Li, J., Sun, J., & Liu, B. (2027). piR-34379 inhibits bladder cancer progression and reverses cisplatin resistance by downregulating ACAT2-mediated PKM2 lactylation. Cellular Signalling, 150, 112978. https://doi.org/10.1016/j.cellsig.2026.112978
Vancouver
Huang S, Li Y, Shi Y, Zhang F, Lu D, Yu K, et al. piR-34379 inhibits bladder cancer progression and reverses cisplatin resistance by downregulating ACAT2-mediated PKM2 lactylation. Cellular Signalling. 2027;150:112978. doi:10.1016/j.cellsig.2026.112978
BibTeX
@article{Huang2027,
author = {Huang, Suyuelin and Li, Yuxiao and Shi, Yuchen and Zhang, Fenghao and Lu, Dingheng and Yu, Kai and Zhang, Jiawei and Yuan, Jihuan and Wang, Xiao and Ma, Xueyou and Li, Jiangfeng and Sun, Jiazhu and Liu, Ben},
title = {piR-34379 inhibits bladder cancer progression and reverses cisplatin resistance by downregulating ACAT2-mediated PKM2 lactylation},
journal = {Cellular Signalling},
year = {2027},
volume = {150},
pages = {112978},
doi = {10.1016/j.cellsig.2026.112978}
}
EUVIMED